FDA OK's Merck/ALK sublingual hay fever drug Ragwitek
This article was originally published in Scrip
Executive Summary
Merck and ALK-Abell� won approval from the FDA on 17 April for the companies' once-daily sublingual hay fever immunotherapy Ragwitek, the first allergen extract available in the US administered under the tongue to treat short ragweed pollen-induced allergic rhinitis with or without conjunctivitis in adults 18-65 years.